Markus Peck‐Radosavljevic
Impact in
- Hepatology top 0.02%
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Liver physiology and pathology
- Epidemiology top 0.1%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
Papers in
- Hepatology 253
- Liver Disease and Transplantation 117
- Hepatitis C virus research 86
- Hepatocellular Carcinoma Treatment and Prognosis 72
- Epidemiology 143
- Liver Disease Diagnosis and Treatment 118
- Hepatitis B Virus Studies 26
- Co-authors
- Wolfgang Sieghart (65 shared papers)Michael Trauner (113 shared papers)Thomas Reiberger (135 shared papers)Matthias Pinter (43 shared papers)Arnulf Ferlitsch (77 shared papers)Mattias Mandorfer (82 shared papers)Philipp Schwabl (68 shared papers)Dominique Charles Valla (5 shared papers)
- Journals
- Journal of Hepatology (72 papers)Liver International (27 papers)Alimentary Pharmacology & Therapeutics (17 papers)Hepatology (12 papers)United European Gastroenterology Journal (9 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Markus Peck‐Radosavljevic
391 papers receiving 21.2k citations
Markus Peck‐Radosavljevic's Hit Papers
Peers
Comparison fields: 5 of 151
- Hepatology 12.2k
- Epidemiology 8.2k
- Cancer Research 1.3k
- Oncology 2.2k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Markus Peck‐Radosavljevic
This map shows the geographic impact of Markus Peck‐Radosavljevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Peck‐Radosavljevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Peck‐Radosavljevic more than expected).
Fields of papers citing papers by Markus Peck‐Radosavljevic
This network shows the impact of papers produced by Markus Peck‐Radosavljevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Peck‐Radosavljevic. The network helps show where Markus Peck‐Radosavljevic may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Peck‐Radosavljevic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 404 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1063 |
| 2 | The burden of liver disease in Europe: A review of available epidemiological data Hit paper breakdown → | 2013 | 1053 |
| 3 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC Hit paper breakdown → | 2021 | 1006 |
| 4 | Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib Hit paper breakdown → | 2014 | 500 |
| 5 | Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study Hit paper breakdown → | 2022 | 479 |
| 6 | 2010 | 384 | |
| 7 | 2013 | 376 | |
| 8 | Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2016 | 374 |
| 9 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 362 |
| 10 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Hit paper breakdown → | 2018 | 306 |
| 11 | 2014 | 291 | |
| 12 | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma Hit paper breakdown → | 2019 | 291 |
| 13 | 2013 | 280 | |
| 14 | 2012 | 275 | |
| 15 | 2015 | 268 | |
| 16 | 2016 | 253 | |
| 17 | 2012 | 252 | |
| 18 | Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score Hit paper breakdown → | 2021 | 226 |
| 19 | 2016 | 219 | |
| 20 | 2016 | 215 |
About Markus Peck‐Radosavljevic
Markus Peck‐Radosavljevic is a scholar working on Hepatology, Epidemiology, Oncology, Hematology and Pathology and Forensic Medicine, having authored 404 papers that have together received 21.7k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (118 papers), Liver Disease and Transplantation (117 papers), Hepatitis C virus research (86 papers), Hepatocellular Carcinoma Treatment and Prognosis (72 papers), Hepatitis B Virus Studies (26 papers), Platelet Disorders and Treatments (19 papers), Organ Transplantation Techniques and Outcomes (18 papers) and Systemic Lupus Erythematosus Research (12 papers). The work is most often cited by research in Hepatology (12.2k citations), Epidemiology (8.2k citations), Cancer Research (1.3k citations), Oncology (2.2k citations) and Pathology and Forensic Medicine (1.4k citations). Markus Peck‐Radosavljevic has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Wolfgang Sieghart, Michael Trauner, Thomas Reiberger, Matthias Pinter, Arnulf Ferlitsch, Mattias Mandorfer, Philipp Schwabl, Dominique Charles Valla, Martin Blachier and Françoise Roudot‐Thoraval. Their work appears in journals such as Journal of Hepatology, Liver International, Alimentary Pharmacology & Therapeutics, Hepatology and United European Gastroenterology Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.